Cargando…

Calling for rapid development of a safe and effective MERS vaccine

The geographic spread and rapid increase in the cases of Middle East respiratory syndrome (MERS) caused by a novel coronavirus (MERS-CoV) during the past two months have raised concern about its pandemic potential. Here we call for the rapid development of an effective and safe MERS vaccine to contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hotez, Peter J., Bottazzi, Maria Elena, Tseng, Chien-Te K., Zhan, Bin, Lustigman, Sara, Du, Lanying, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Masson SAS 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128618/ https://www.ncbi.nlm.nih.gov/pubmed/24931059 http://dx.doi.org/10.1016/j.micinf.2014.05.002

Ejemplares similares

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2014)

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
por: Nyon, Mun Peak, et al.
Publicado: (2018)

Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi
por: Zhan, Bin, et al.
Publicado: (2022)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Learning from the past: development of safe and effective COVID-19 vaccines
por: Su, Shan, et al.
Publicado: (2020)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
por: Jiang, Shibo, et al.
Publicado: (2015)

The Onchocerciasis Vaccine for Africa—TOVA—Initiative
por: Hotez, Peter J., et al.
Publicado: (2015)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”
por: Bottazzi, Maria Elena, et al.
Publicado: (2019)

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies
por: Jiang, Shibo, et al.
Publicado: (2020)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection
por: Arumugam, Sridhar, et al.
Publicado: (2016)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates
por: Wang, Jing, et al.
Publicado: (2012)

Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans
por: George, Parakkal Jovvian, et al.
Publicado: (2019)

The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
por: Hess, Jessica A., et al.
Publicado: (2016)

Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

Middle East respiratory syndrome: current status and future prospects for vaccine development
por: Du, Lanying, et al.
Publicado: (2015)

Development of SARS vaccines and therapeutics is still needed
por: Jiang, Shibo, et al.
Publicado: (2013)

Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils
por: Zhan, Bin, et al.
Publicado: (2018)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

Developing a low-cost and accessible COVID-19 vaccine for global health
por: Hotez, Peter J., et al.
Publicado: (2020)

MERS Coronavirus: An Emerging Zoonotic Virus
por: Li, Fang, et al.
Publicado: (2019)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

Human Schistosomiasis Vaccines as Next Generation Control Tools
por: Hotez, Peter J., et al.
Publicado: (2023)

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
por: Zhang, Naru, et al.
Publicado: (2020)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_72ndvlaeqesl5293o4vub15ahs